6 May 2021

Oculis S.A., a late-stage biopharmaceutical company focused on developing transformative ophthalmic treatments to improve the sight and lives of patients has closed an oversubscribed USD 57m Series C financing round. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining several of the company’s existing investors.

The VISCHER-team advising Oculis is led by Matthias Staehelin (Partner) with Vincent Reardon (Managing Associate) (both Corporate).

Press release

Categories: China Desk, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.